Get started
Innate Pharma S.A.Innate Pharma S.A.Innate Pharma S.A.

Innate Pharma S.A.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

IPHA chart


Full chart

IPHA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪166.04 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.46 USD
Net income (FY)
‪−8.18 M‬ USD
Revenue (FY)
‪56.11 M‬ USD
Shares float
—
Beta (1Y)
0.11

About INNATE PHARMA


Sector
Health Technology
CEO
Jonathan Dickinson
Headquarters
Marseille
Website
innate-pharma.com
Founded
1999
FIGI
BBG009ZCBVG7
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

IPHA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.